Cargando…
A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury
BACKGROUND: Pentobarbital pharmacokinetics (PK) remain elusive and the therapeutic windows narrow. Administration is frequent in critically ill children with refractory status epilepticus (SE) and severe traumatic brain injury (sTBI). OBJECTIVES: To investigate pentobarbital PK in SE and sTBI patien...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338388/ https://www.ncbi.nlm.nih.gov/pubmed/37247187 http://dx.doi.org/10.1007/s40262-023-01249-z |
_version_ | 1785071617906311168 |
---|---|
author | Ketharanathan, Naomi Lili, Anastasia de Vries, Julia M. Penning Wildschut, Enno D. de Hoog, Matthijs Koch, Birgit C. P. de Winter, Brenda C. M. |
author_facet | Ketharanathan, Naomi Lili, Anastasia de Vries, Julia M. Penning Wildschut, Enno D. de Hoog, Matthijs Koch, Birgit C. P. de Winter, Brenda C. M. |
author_sort | Ketharanathan, Naomi |
collection | PubMed |
description | BACKGROUND: Pentobarbital pharmacokinetics (PK) remain elusive and the therapeutic windows narrow. Administration is frequent in critically ill children with refractory status epilepticus (SE) and severe traumatic brain injury (sTBI). OBJECTIVES: To investigate pentobarbital PK in SE and sTBI patients admitted to the paediatric intensive care unit (PICU) with population-based PK (PopPK) modelling and dosing simulations. METHODS: Develop a PopPK model with non-linear mixed-effects modelling (NONMEM(®)) with retrospective data (n = 36; median age 1.3 years; median weight 10 kg; 178 blood samples) treated with continuous intravenous pentobarbital. An independent dataset was used for external validation (n = 9). Dosing simulations with the validated model evaluated dosing regimens. RESULTS: A one-compartment PK model with allometrically scaled weight on clearance (CL; 0.75) and volume of distribution (V(d); 1) captured data well. Typical CL and V(d) values were 3.59 L/70 kg/h and 142 L/70 kg, respectively. Elevated creatinine and C-reactive protein (CRP) levels significantly correlated to decreased CL, explaining 84% of inter-patient variability, and were incorporated in the final model. External validation using stratified visual predictive checks showed good results. Simulations demonstrated patients with elevated serum creatinine and CRP failed to achieve steady state yet progressed to toxic levels with current dosing regimens. CONCLUSIONS: The one-compartment PK model of intravenous pentobarbital described data well whereby serum creatinine and CRP significantly correlated with pentobarbital CL. Dosing simulations formulated adjusted dosing advice in patients with elevated creatinine and/or CRP. Prospective PK studies with pharmacodynamic endpoints, are imperative to optimise pentobarbital dosing in terms of safety and clinical efficacy in critically ill children. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40262-023-01249-z. |
format | Online Article Text |
id | pubmed-10338388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-103383882023-07-14 A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury Ketharanathan, Naomi Lili, Anastasia de Vries, Julia M. Penning Wildschut, Enno D. de Hoog, Matthijs Koch, Birgit C. P. de Winter, Brenda C. M. Clin Pharmacokinet Original Research Article BACKGROUND: Pentobarbital pharmacokinetics (PK) remain elusive and the therapeutic windows narrow. Administration is frequent in critically ill children with refractory status epilepticus (SE) and severe traumatic brain injury (sTBI). OBJECTIVES: To investigate pentobarbital PK in SE and sTBI patients admitted to the paediatric intensive care unit (PICU) with population-based PK (PopPK) modelling and dosing simulations. METHODS: Develop a PopPK model with non-linear mixed-effects modelling (NONMEM(®)) with retrospective data (n = 36; median age 1.3 years; median weight 10 kg; 178 blood samples) treated with continuous intravenous pentobarbital. An independent dataset was used for external validation (n = 9). Dosing simulations with the validated model evaluated dosing regimens. RESULTS: A one-compartment PK model with allometrically scaled weight on clearance (CL; 0.75) and volume of distribution (V(d); 1) captured data well. Typical CL and V(d) values were 3.59 L/70 kg/h and 142 L/70 kg, respectively. Elevated creatinine and C-reactive protein (CRP) levels significantly correlated to decreased CL, explaining 84% of inter-patient variability, and were incorporated in the final model. External validation using stratified visual predictive checks showed good results. Simulations demonstrated patients with elevated serum creatinine and CRP failed to achieve steady state yet progressed to toxic levels with current dosing regimens. CONCLUSIONS: The one-compartment PK model of intravenous pentobarbital described data well whereby serum creatinine and CRP significantly correlated with pentobarbital CL. Dosing simulations formulated adjusted dosing advice in patients with elevated creatinine and/or CRP. Prospective PK studies with pharmacodynamic endpoints, are imperative to optimise pentobarbital dosing in terms of safety and clinical efficacy in critically ill children. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40262-023-01249-z. Springer International Publishing 2023-05-29 2023 /pmc/articles/PMC10338388/ /pubmed/37247187 http://dx.doi.org/10.1007/s40262-023-01249-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Ketharanathan, Naomi Lili, Anastasia de Vries, Julia M. Penning Wildschut, Enno D. de Hoog, Matthijs Koch, Birgit C. P. de Winter, Brenda C. M. A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury |
title | A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury |
title_full | A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury |
title_fullStr | A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury |
title_full_unstemmed | A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury |
title_short | A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury |
title_sort | population pharmacokinetic model of pentobarbital for children with status epilepticus and severe traumatic brain injury |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338388/ https://www.ncbi.nlm.nih.gov/pubmed/37247187 http://dx.doi.org/10.1007/s40262-023-01249-z |
work_keys_str_mv | AT ketharanathannaomi apopulationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT lilianastasia apopulationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT devriesjuliampenning apopulationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT wildschutennod apopulationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT dehoogmatthijs apopulationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT kochbirgitcp apopulationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT dewinterbrendacm apopulationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT ketharanathannaomi populationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT lilianastasia populationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT devriesjuliampenning populationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT wildschutennod populationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT dehoogmatthijs populationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT kochbirgitcp populationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury AT dewinterbrendacm populationpharmacokineticmodelofpentobarbitalforchildrenwithstatusepilepticusandseveretraumaticbraininjury |